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ABSTRACT
Objective: This study aims to determine the relationship of serum levels of anti-phenolic glycolipid (PGL-1), immunoglobulin M (IgM), and anti-PGL-1 
immunoglobulin G (IgG) with bacterial index (BI) values in multibacillary (MB) leprosy.
Methods: This study was an observational study with a cross-sectional design. A total of 30 study samples were examined for a Slit Skin Smear and 
examined serum levels of IgM and IgG Anti PGL-1 antibodies by ELISA method.
Results: The results showed the higher the BI value, the serum levels of IgM anti-PGL-1 and IgG anti-PGL-1 increased.
Conclusion: There was a significant relationship between IgM anti-PGL-1 with BI value in MB leprosy (p<0.05), but there was no significant 
relationship between IgG anti-PGL-1 with BI value in MB leprosy (p>0.05). IgM anti-PGL-1 has more role in increasing the value of BI in MB leprosy.
Keywords: Immunoglobulin M-anti-phenolic glycolipid 1, Immunoglobulin G-anti-phenolic glycolipid, Bacterial index, Slit skin smear.
INTRODUCTION
Leprosy is still a public health problem in various countries [1]. These 
microbial infections are endemic in more than 15 countries and around 
250,000 new cases of leprosy are reported each year from around the 
world [2,3]. During 2012 new cases of leprosy were reported as many as 
232,857 cases and are expected to reach 4 million cases by 2020 [1,4]. 
Although have completed therapy many people develop leprosy 
reactions, disability and neurological dysfunction due to peripheral 
nerve damage that is irreversible [4]. This disease is also closely related 
to myths about stigma, death, and mutilation. This perception raises 
prejudice, discrimination, and social exclusion so that sufferers are 
not only physically ill but also mentally ill and affect their personal and 
professional lives [5].
Indonesian in 2013 ranks third in the world after India and Brazil with 
the number of cases leprosy as many as 16,856 cases and the number 
of second level of disability among new patients as much as 9.86% [6]. 
New cases of leprosy in 2015 were reported as many as 17,202 cases 
with 84.5% of which is a type of Multibacillary (MB). Level 2 disability 
rate in 2015 was 6.60 per 1 million population. North Sulawesi Province 
ranks highest with a disability rate of 2 per 1,000,000 population 
in 2015 of 21.14% followed by other regions such as West Papua 
(19.51%) and Gorontalo (18.53%) [7]. In 2014 in Jambi Province, there 
were nine reported new cases of Pausibasilar (PB) and 68 Multibasilar 
(MB) types. The district with the highest number of new leprosy cases 
is Tanjung Jabung Timur district with 34 cases with a prevalence of 
4.48 cases per 10,000 population [8]. The number of leprosy patients 
visiting the Skin and Sex Polyclinic of Raden Mattaher Jambi Hospital 
from 2014 to 2016 was 29 people with 18 male patients and 11 female 
patients.
Leprosy is a chronic granulomatous infectious disease caused by the 
obligate intracellular bacillus Mycobacterium leprae, mainly affecting 
the skin and peripheral nerves and can lead to disability and obvious 
physical damage [3,5]. The criteria for leprosy diagnosis according 
to the World Health Organization (WHO) are based on three cardinal 
symptoms, namely macular erythema or numb hypopigmentation, 
thickening of peripheral nerves and smears of acid-resistant bacilli or 
positive skin biopsy [3]. Slit Skin Smear (SSS) is still a laboratory method 
for confirmation and classification of the clinical form of leprosy. The 
WHO classifies all leprosy cases with positive SSS results regardless 
of the number of lesions as MB leprosy. Therefore, the results of a 
papalbacillary (PB) leprosy smear will always be negative [9].
MB leprosy arises in patients with a low cellular immune response to 
M. leprae, so it has a high bacillary burden and is a source of infection. 
MB leprosy sufferers are primarily responsible for the transmission of 
M. leprae in endemic areas [10]. M. leprae cannot be cultured in vitro; 
thus finding smear with a microscope remains a standard diagnostic 
technique. The number of bacilli in each microscope field or bacterial 
index (BI) was calculated according to the Ridley index for skin smears 
(ear lobes and skin lesions). Classification according to the WHO (1988) 
included all lepers with positive BI in the MB group. In lepromatous 
leprosy, BI results are always positive >2 if accompanied by globus on 
microscopic examination [11].
Slit-Skin Smear examination is an essential screening procedure for all 
sufferers suspected of having leprosy. In addition to establishing the 
diagnosis, classification of diseases (papalbacillary and MB) and the 
continued observation of therapeutic response, SSS is also very helpful 
in studying the distribution of M. leprae to the skin and ascertain the 
degree of infectious and severity of the disease. M. leprae is usually 
found in large quantities in the dermis of MB leprosy sufferers. Because 
it requires at least 104 bacilli/g tissue to give positive SSS results, SSS 
usually gives negative results on papillary bacilli leprosy which only has 
a small amount of bacilli [12].
Phenolic glycolipid-1 (PGL-1) M. leprae has high sugar content 
immunogenicity and is a very important virulence factor. Infection 
by M. leprae in MB leprosy results in the emergence of cell-mediated 
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humoral responses and the production of non-protective antibodies. 
The presence of PGL-1 antigens will stimulate the formation of 
antibodies both immunoglobulin M (IgM) and immunoglobulin G (IgG). 
IgG antibodies show an immune response to chronic diseases, meaning 
that even if the patient is not sick, they have been exposed to M. leprae 
antigens. IgM is the opposite, IgM against anti-PGL-I shows the patient 
has an acute immune response or is suffering from leprosy [13].
According to Manzel et al., (1987) with this PGL-1 antigen, it is unlikely 
that a cross reaction with other mycobacteria will occur. It has been 
observed that IgM antibodies with PGL-1 correlate well with clinical 
activity. Positive results of serum IgM antibodies in someone without a 
clinical picture suggest the possibility of a subclinical infection. The results 
of the anti-PGL-1 IgM ELISA examination have a threshold value for anti-
PGL-1 IgM antibodies that is ≥605 u/ml [14] whereas the anti PGL-1 IgG 
antibody titer has a cutoff value, which is about nilai 630 u/ml [15].
MB leprosy arises in patients with a low cellular immune response to M. 
leprae, so it has a high bacillary burden and is a source of infection [10]. 
Skin smear examination results give positive results according to the 
number of bacilli accompanied by elevated levels of M. leprae-specific 
IgM antibodies [16].
Based on the description above it is important to determine the 
relationship of serum levels of IgM-anti-PGL 1 and IgG anti-PGL 1 with 
BI values in MB leprosy.
MATERIAL AND METHODS
This research was an observational cross sectional design study. This 
research was conducted in February to November 2019.
Patients
The research subjects were MB leprosy patients of new or old cases who 
came for treatment at Leprosy Hospital Dr. Rivai Abdullah Palembang 
and Puskesmas Sukajadi, Banyuasin District, South Sumatra Province 
in the study period that met the inclusion and exclusion criteria. MB 
leprosy sufferers do history taking, physical examination, supporting 
examination in the form of smears of skin incisions to diagnose, 
determine the type of leprosy, and know the value of the BI.
Samples
Serum examined blood levels of IgM and IgG antibodies anti-PGL-1 
ELISA and using a kit made by Leprosy Laboratory Institute of Tropical 
Disease, Airlangga University, Surabaya.
ELISA methods
The ELISA examination procedure to determine the PGL-1 antibody 
level is as follows 50 µl of coating buffer and NT-P-BSA working solution 
were inserted into the microcaps that had been divided according to 
the scheme and incubated for 1 h 37°C. The microcrafts were washed 
3× with washing buffer (PBST solution). Blocking buffer 200 µl was 
inserted into the microplatograph, incubated for 1 h 37°C. Blocking 
buffer was discarded, 50 µl serums were diluted with dilution buffer 
(1: 300), into the microplatograph, and reincubated for 1 h 37°C. 
Wash microplate with washing buffer 3 times. 50 µl second antibodies 
(IgG/IgM are placed according to the scheme) into the microplate, 
incubated for 1 h 37°C (IgG/IgM diluted with dilution buffer as much 
as 1: 2000). Microplate was washed again with washing buffer 3 times. 
Substrate solution is given as much as 100 µl into the microplate to 
yellow/orange. The staining reaction is stopped after±10–30 min by 
adding 100 µl stopping solution. Absorption prices (OD) with Elisa 
Reader are calculated.
RESULTS
The study was conducted at Leprosy Hospital Dr. Rivai Abdullah and 
Puskesmas Sukajadi, Banyuasin Regency, South Sumatra Province. 
Patients obtained from outpatient polyclinics in hospitals and health 
centers. During the period December 2017 to March 2018, there were 
30 subjects with MB leprosy. A total of 17 MB leprosy (MB) subjects 
were obtained from Dr. Leprosy Hospital Rivai Abdullah and 13 subjects 
from the Sukajadi Community Health Center in Banyuasin District. The 
data on the characteristics of these respondents can be explained in the 
following Table 1.
Based on Table 1, it is found that the most age group of leprosy patients 
is the age group of 31–40 years, namely, ten people (33.3%). More 
male sex was found, 26 people (86.7%). Research subjects with more 
elementary school education levels were 17 people (56.7%). Farmers 
are the most work, ten people (33.3%). In this study, BI values were 
divided into two groups as shown in Table 2.
Table 2 shows that as many as 13 people (43.3%) of MB leprosy patients 
had BI values <3 and 17 people (56.7%) BI values ≥3.
The results showed that the relationship of serum levels of anti-PGL-1 
IgM with BI values is shown in Table 3 below.
Table 3 shows the results of the Independent Sample Test statistics 
obtained p=0.036 (p<0.05), meaning that statistically there are 
significant differences between serum levels of anti-PGL-1 IgM with BI 
values in MB leprosy. The results showed that the relationship of serum 
levels of IgG anti-PGL-1 with the index value of bacteria in MB leprosy 
is shown in Table 4 below.
Table 4 shows the results of the Independent Sample Test statistical 
test obtained p=0.954 (p>0.05), meaning that there is no statistically 
significant difference between serum levels of anti-PGL-1 IgG with 
BI values in MB leprosy. The results obtained from the Logistic 
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Table 2: Bacteria index values in research subjects
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Regression test are p value IgM anti-PGL-1=0.013 (p<0.05) and IgG 
anti-PGL-1=0.56, meaning IgM anti-PGL-1 has more role in increasing 
BI value in MB leprosy.
DISCUSSION
Data on the characteristics of the research subjects showed more male 
sexes namely 26 people (86.7%). This study is similar to research in 
Brazil, where the distribution of male sex in MB leprosy patients was 
51.28% and women were 48.71% [9]. This can be explained because 
men interact more in social activities outside the home so that they 
have a higher risk of exposure to leprosy. Whereas women, for the 
most part, did not interact much with the community, were more 
silent, and were unable to raise their health problems to surrounding 
communities. This is mainly due to social stigma, low dependency on 
economic and social status, personal stigma, and gender insensitivity 
[17]. MB leprosy cases were found in the age range 31–40 years, 10 
people (33.3%) and 21–30 years as many as eight people (26.7%). 
Silva (2017) reports similar results, that new leprosy cases average 
age 40 years with an age range of 15–44 years as much as 51.28%. 
Leprosy mainly concerns individuals in the economically active 
period of the 20–60 year age range [9]. Martin (2016) reports that 
54% of people with leprosy are in that age range. The tendency of 
people with leprosy in old adulthood may be caused by reduced 
exposure to M. leprae in children and the incubation period for MB 
leprosy for a long time. In addition, there is a role for age-related 
immune changes and increased susceptibility to infectious diseases in 
the form of decreased monocyte and neutrophil function, phagocyte 
capacity, antigen presentation, and cytokine profile changes from 
Th-1 to Th-2 [10].
Research subjects with more elementary school education levels were 
17 people (56.7%). The characteristics of the level of education of this 
study are consistent with those obtained in other studies, where many 
people affected by leprosy suffered by individuals with low education, 
weak socio economic and poor basic health conditions [18]. Farmers 
constituted the most work in the study subjects, ten people (33.3%). 
In fulfilling the needs of farmers, working is much heavier and has high 
mobility so that low immunity is consequently susceptible to MB type 
leprosy [13].
M. leprae cannot be cultured in vitro; thus finding smear with a 
microscope remains a standard diagnostic technique. The number of 
bacilli in each microscope field or BI was calculated according to the 
Ridley index for skin smears (ear lobes and skin lesions). Classification 
according to the WHO (1988) included all lepers with positive BI in the 
MB group. In lepromatous leprosy, BI results are always positive > 2 if 
accompanied by globus on microscopic examination. 11 Slit-Skin Smear 
examinations is an essential screening procedure for all sufferers 
suspected of having leprosy. In addition to establishing the diagnosis, 
classification of diseases (papalbacillary and MB) and the continued 
observation of therapeutic response, SSS is also very helpful in studying 
the distribution of M. leprae to the skin and ascertain the degree of 
infectious and severity of the disease. M. leprae is usually found in large 
quantities in the dermis of MB leprosy sufferers. Because it requires 
at least 10 4 bacilli/gr tissue to give positive SSS results, SSS usually 
gives negative results on papillary bacilli leprosy which only has a small 
amount of bacilli [12].
PGL-1 is able to suppress host immune responses by direct inhibition 
of Toll-like receptors or bind to lectin receptors (CR-3) to facilitate 
the entry of mycobacteria into host cells and inhibit TNF-α secretion 
by macrophages. The PGL-1 saccharide content also suppresses anti-
inflammatory processes by reducing the production of other cytokines 
induced by TLR-2, namely, IL-6, IL-1β, and CCL2 and causes low 
activation and maturation of dendritic cells and reduces its ability to 
induce T cell responses [19]. Adaptive immune response will arise 
if there is a race of M leprae antigens on CD4+Th lymphocytes. In 
MB type leprosy, Th-2 CD4 + will secrete IL-4 and IL-10 which then 
activates B lymphocytes. Active B lymphocytes will proliferate and 
produce immunoglobulin (Ig) either IgM or IgG. IgM against anti-
PGL-1 indicates that the patient has an acute immune response or is 
suffering from leprosy and IgG shows an immune response to a chronic 
disease or even if the patient is not sick, but has been exposed to M. 
leprae antigen. Serological examination of leprosy is limited in use to 
the lepromatous/MB spectrum, because humoral immune responses 
play a role. The PGL-1 component can stimulate an immune response, 
but the immune response that occurs is not strong enough to eradicate 
M. leprae [13]. The high antibody titer is closely related to the BI, and 
the titer will decrease following the anti-leprosy treatment given [20].
In this study, from 30 sample subjects, an increase in mean serum IgM 
PGL-1 levels was accompanied by an increase in the number of bacilli in 
patients who were shown by BI values. The mean serum level of leprosy 
patients with BI value <3 was 12794.96 u/ml and leprosy patients with 
BI value ≥3 was 31849.38 u/ml. Likewise, the mean serum IgG PGL-
1 level with an average value of 19410.23 u/ml for BI values <3 and 
22968.50 u/ml for BI values ≥3. The presence of antibodies to PGL-1 
is related to the number of bacteria (BI) M. leprae in lepers [13]. Moura 
et al. (2008) reported in their study that there was a higher PGL-1 
antibody titer in the lepromatous type compared to the tuberculoid 
type, and that the titer tended to decrease with effective treatment, 
statistically there was a significant association between the number of 
bacteria and antibody titer. PGL-1 antigens can cause specific humoral 
immune responses, so they can be used in sero-diagnostic examinations 
of leprosy, but cannot stimulate cellular immune responses so they 
cannot cause immunity [21].
The results of this study indicate that the higher the BI value, the serum 
levels of IgM and IgG anti-PGL-1 will increase. Skin smear examination 
results give positive results in accordance with the number of bacilli 
accompanied by increased levels of M. leprae specific antibodies [16]. 
From the statistical test results obtained p=0.036 (p<0.05), meaning 
that there is a significant difference between serum levels of anti-
PGL-1 IgM with leprosy severity based on BI values. However, although 
there was an increase in serum IgG levels to an increase in BI values 
the statistical results showed no significant difference with a value of 
p=0.954 (p>0.05).
The results of this study are similar to studies conducted by Schuring 
(2006) and Fabri (2015) which state that there is a positive correlation 
between antibody titers and the index of leprosy bacteria. Schuring 
(2006) reported that seropositive levels increased according to the 
value of BI, that is, Adjusted Odds Ratio (aOR) of patients with BI ≤2 
was 6.33 (95% CI 2.42–16.5) and the aOR of patients with IB> 2 was 59, 
0 (95% CI 25.0–139) compared with BI patients who were negative [16]. 
Table 3: Relationship between serum levels of IgM anti‑Phenolic 
Glycolipid‑1 with values BI in MB leprosy
















Table 4: Relationship between serum levels of IgG anti‑Phenolic 
Glycolipid‑1 with values BI in MB leprosy
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Research by Rawlinson et al. states that there is an increase in levels of 
anti-PGL-1 IgG in MB leprosy compared to papillaryasila. In MB leprosy, 
there is a defect in T lymphocytes (T helper and T suppressor). T cells 
control B cell proliferation, so that uncontrolled B cell proliferation 
causes an increase in IgG levels in MB leprosy [22].
Interpretation of anti-PGL-1 IgG results is needed in the examination 
of anti-PGL IgM 1. PGL-1 antigens can trigger IgM antibodies obtained 
in tissues infected with M leprae and can last for a very long time 
even though the M. leprae bacillus is dead. The antibody response 
in particular the IgM class shows that IgM does not depend on the 
response of lymphocyte T cells to this glycolipid antigen. In contrast 
to the IgG response which is dominated by LAM major carbohydrate 
antigens [15].
The results obtained from the Logistic Regression test are p value of 
anti-PGL-1 IgM=0.013 and anti-PGL-1 IgG=0.56, meaning that anti-
PGL-1 IgM has more role in increasing BI value in MB leprosy. This can 
be explained by the fact that IgM antibodies appear 1–2 weeks after 
the onset of an antigen or germ attack, and will stay 2–3 months more 
depending on the presence of germ persistence. Detection of serum IgM 
with high levels specific to certain microbes is consistent with ongoing 
or recent infection in the host. Conversely, IgG titers will increase 
2–3 weeks after infection and will be detected throughout life. High 
IgG titers indicate that the patient has been exposed to germ antigens 
and contact with leprosy patients has occurred in a long time, possibly 
having months or annual contact with lepers [23].
CONCLUSION
The BI value shows the severity of leprosy. Serum IgM levels of 
anti- PGL-1 are significantly related to BI values, where the higher the 
BI value, the serum levels of anti-PGL-1 IgM will increase. The higher 
the BI value, the serum levels of IgG anti- PGL-1 will increase, but this 
relationship is not statistically significant. The most important factor in 
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